- Home
- GEG vs TVGN Comparison
GEG vs TVGN Comparison
Compare GEG & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GEG | TVGN |
|---|---|---|
| Founded | 1994 | 2020 |
| Country | United States | United States |
| Employees | 50 | N/A |
| Industry | Computer Software: Prepackaged Software | Blank Checks |
| Sector | Technology | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.7M | 63.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GEG | TVGN |
|---|---|---|
| Price | $2.13 | $8.50 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 5.1K | ★ 22.7K |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.80 | $0.14 |
| 52 Week High | $3.51 | $10.76 |
Technical Indicators
Market Signals| Indicator | GEG | TVGN |
|---|---|---|
| Relative Strength Index (RSI) | 54.31 | 60.05 |
| Support Level | $2.06 | $0.47 |
| Resistance Level | $2.19 | $9.40 |
| Average True Range (ATR) | 0.08 | 0.88 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 54.17 | 62.65 |
Price Performance
Historical ComparisonAbout GEG Great Elm Group Inc.
Great Elm Group Inc operates as an alternative asset manager focused on growing a scalable and diversified portfolio of long-duration and permanent capital vehicles across credit, real estate, specialty finance, and other alternative strategies. Along with its subsidiaries, it manages Great Elm Capital Corp, a publicly traded business development company, and Monomoy Properties REIT, LLC, an industrial-focused real estate investment trust, in addition to other investments.
About TVGN Tevogen Bio Holdings Inc.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.